Kidney Cancer Vaccine Shows No Boost in Survival

FRIDAY, July 3 (HealthDay News) -- The new vaccine vitespen didn't increase recurrence-free survival among kidney cancer patients who'd had surgery, say U.S. researchers. Surgery is standard treatment for kidney cancer, but many patients are at risk of cancer recurrence because there is no effective adjuvant treatment, according to background information in the study by Dr. Christopher Wood, of the M.D. Anderson Cancer Center in Houston, and... [read full story]